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Abstract
Introduction: The N9831 trial demonstrated the efficacy of adjuvant trastuzumab for patients with human epidermal
growth factor receptor 2 (HER2) locally positive tumors by protein or gene analysis. We used the 21-gene assay to
examine the association of quantitative HER2 messenger RNA (mRNA) gene expression and benefit from trastuzumab.
Methods: N9831 tested the addition of trastuzumab to chemotherapy in stage I–III HER2-positive breast cancer. For
two of the arms of the trial, doxorubicin and cyclophosphamide followed by paclitaxel (AC-T) and doxorubicin and
cyclophosphamide followed by paclitaxel and trastuzumab concurrent chemotherapy-trastuzumab (AC-TH), recurrence
score (RS) and HER2 mRNA expression were determined by the 21-gene assay (Oncotype DX®) (negative <10.7, equivocal
10.7 to <11.5, and positive ≥11.5 log2 expression units). Cox regression was used to assess the association of HER2
expression with trastuzumab benefit in preventing distant recurrence.
Results: Median follow-up was 7.4 years. Of 1,940 total patients, 901 had consent and sufficient tissue. HER2 by reverse
transcriptase polymerase chain reaction (RT-PCR) was negative in 130 (14 %), equivocal in 85 (9 %), and positive in 686
(76 %) patients. Concordance between HER2 assessments was 95 % for RT-PCR versus central immunohistochemistry
(IHC) (>10 % positive cells = positive), 91 % for RT-PCR versus central fluorescence in situ hybridization (FISH)
(≥2.0 = positive) and 94 % for central IHC versus central FISH. In the primary analysis, the association of HER2
expression by 21-gene assay with trastuzumab benefit was marginally nonsignificant (nonlinear p = 0.057). In
hormone receptor-positive patients (local IHC) the association was significant (p = 0.002). The association was
nonlinear with the greatest estimated benefit at lower and higher HER2 expression levels.
Conclusions: Concordance among HER2 assessments by central IHC, FISH, and RT-PCR were similar and high.
Association of HER2 mRNA expression with trastuzumab benefit as measured by time to distant recurrence was
nonsignificant. A consistent benefit of trastuzumab irrespective of mHER2 levels was observed in patients with
either IHC-positive or FISH-positive tumors. Trend for benefit was observed also for the small groups of patients
with negative results by any or all of the central assays.
Trial registration: Clinicaltrials.gov NCT00005970. Registered 5 July 2000.
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Introduction
The human epidermal growth factor receptor 2 gene
(HER2) has been reported to be amplified in 15–20 %
of human breast cancers [1, 2]. HER2 gene amplifica-
tion and protein overexpression are prognostic markers
for aggressive disease and predictive markers for specific
targeted therapies, including trastuzumab, pertuzumab,
and lapatinib [3, 4]. Reliable testing methodology is critical
and multiple discussions and publications related to this
issue have been presented, addressing not only test reli-
ability, and definition of “positivity,” but also which tests
may best help predict the efficacy of anti-HER2 therapies
for patients; however, the optimal target: protein, RNA, or
DNA, and type of detection assay [immunohistochemistry
(IHC), reverse transcriptase polymerase chain reaction
(RT-PCR), or fluorescence in situ hybridization (FISH)]
for HER2 remains controversial [5–16].
Persistent problems with test accuracy were recently
highlighted by both the North Central Cancer Treatment
Group (NCCTG) and National Surgical Adjuvant Breast
and Bowel Project (NSABP) National Cancer Institute-
supported Cancer Cooperative Groups who demonstrated
that approximately 3–7 % of breast cancers formerly
assessed as HER2 positive in local laboratories were called
HER2-normal [IHC <10 % of cells with circumferential
membrane staining; FISH HER2:centromere enumerator
probe for chromosome 17 (CEP17) ratio <2.0] when eval-
uated centrally [12, 13, 17]. Interestingly, both studies
demonstrated the efficacy of adjuvant trastuzumab added
to chemoendocrine therapy not only for centrally assessed
HER2-positive breast cancer but also for centrally assessed
HER2-negative breast cancer [12, 13, 17, 18]. The reasons
for the observed benefit in centrally assessed HER2-
negative breast cancer may be due to a wide range of
FISH and IHC methodologic variables including: dif-
fering methods of semiquantitation, differing cutoffs
for positivity, discordance between pathologist inter-
pretation and/or intratumoral heterogeneity. There is
no firm evidence of a differential trastuzumab benefit due
to quantitative differences in HER2 gene copy, messenger
RNA (mRNA) expression or protein levels. In two large
randomized trials a similar benefit of adding trastuzumab
to adjuvant chemotherapy was observed for patients whose
tumors were IHC 3+/FISH-negative or IHC 3+/FISH-
positive; furthermore, no differential benefit was ob-
served as a function of HER2 FISH ratio, HER2 copy
number, or the presence of polysomy [13, 17, 19].
NSABP B-47 will ultimately illuminate whether the
addition of trastuzumab to chemotherapy improves in-
vasive disease-free survival (DFS) in women with resected
node-positive or high-risk node-negative breast cancer
which is reported as HER2-low by all HER2 testing per-
formed. What are lacking in clinical practice today are
highly quantitative, reproducible technology platforms for
HER2 assessment that accurately select for benefit from
anti-HER2 therapies.
The standardized RT-PCR platform used for the 21-gene
assay is highly quantitative and reproducible. In fixed
paraffin-embedded (FPE) tumor tissue its operational
performance shows linearity over a >2000-fold RNA con-
centration range with an average accuracy of 0.3 %, coeffi-
cients of variation for the assay process are below 5.7 %,
and assay variability contributed by instruments, oper-
ators, reagents and day-to-day variation are limited to
less than 0.5 expression units (SD) [20, 21]. Since the dis-
covery of HER2 multiple studies have compared mRNA
expression by PCR with FISH and/or IHC [22–28]. Using
2007 American Society of Clinical Oncology/College of
American Pathologists (ASCO/CAP) guidelines and ex-
cluding equivocal cases by both assays, a high degree of
concordance (97 %) between HER2 mRNA levels by the
Oncotype DX assay and central laboratory FISH was ob-
served in patients from the Kaiser study [22, 29]. A second
HER2 concordance study between RT-PCR and central
IHC in patients from ECOG E2197 also showed a high
concordance (95 %) [23].
The role of quantitative RNA analysis of HER2 as pre-
dictor of benefit from trastuzumab has not been reported
prior to the study reported here. This is a prospectively
designed study to determine if quantitative levels of the
ERBB2 gene expression level as assessed by mRNA coding
for the HER2 protein, quantified by the 21-gene assay and
reported as the HER2 single gene score, are predictive of
the magnitude of benefit from the addition of trastuzumab
to adjuvant chemotherapy in NCCTG (Alliance) N9831.
The hypothesis was that increasing levels of expression
are associated with increasing trastuzumab benefit. A sec-
ondary objective was to evaluate the concordance between
HER2 mRNA expression level and protein assessment by
IHC and gene copy number assessment by FISH.
Methods
Patients
The N9831 trial (the phase III trial of doxorubicin and
cyclophosphamide followed by weekly paclitaxel with or
without trastuzumab as adjuvant treatment for women
with HER2-overexpressing or -amplified node-positive
or high-risk node-negative breast cancer) was approved
by participating institutional review boards (IRBs) [30].
The study had three arms: Arm A, doxorubicin and cyclo-
phosphamide followed by weekly paclitaxel; Arm B, same
as Arm A but followed by 1 year of sequential trastuzumab;
Arm C, same as Arm A but with 1 year of concurrent tras-
tuzumab, started the same day as paclitaxel. Results of the
different arms of the N9831 trial were published in 2011,
demonstrating that although each trastuzumab-containing
arm led to statistically significant better DFS compared to
chemotherapy alone, the largest difference was observed in
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the Arm C versus Arm A comparisons. The present ana-
lyses included only patients randomly assigned to Arms A
or C, enrolled from May 25, 2000 through April 25, 2005,
and tested for HER2 protein overexpression or gene
amplification locally and at a central laboratory (Mayo
Clinic, Rochester, MN, USA). All patients gave consent
to participate.
HER2 IHC and FISH testing methods
IHC staining was performed on paraffin-embedded 5-μm
tissue sections using the HercepTest according to the man-
ufacturer’s instructions (DAKO, Carpinteria, CA, USA)
[12, 31, 32]. Assay control cell lines (SK-BR-3:3+, MDA-
175:1+, MDA-231:0) provided on slides in the HercepTest
kit were analyzed in each assay. Invasive carcinoma cells
(and not benign epithelial or ductal carcinoma in situ cells)
were used for the assessment of HER2 status of the tumor.
Specimens were scored as per the instructions in the tras-
tuzumab package insert. A specimen with at least 10 %
invasive cells with complete membrane staining was
classified as 3+ and considered HER2-positive accord-
ing to pre-ASCO/CAP 2007 guidelines [29].
FISH analysis was performed on deparaffinized 5-μm tis-
sue sections using the PathVysion ERBB2 DNA probe kit
and the ERBB2/centromere 17(HER2/CEP17) probe mix-
ture (Abbott Molecular, Des Plaines, IL, USA) [12, 31, 32].
For each case, a parallel hematoxylin and eosin (H&E)-
stained slide was examined for regions of invasive car-
cinoma by a board-certified pathologist (D.W.V., R.P.K.).
The completed tissue section was scanned by two certified
cytogenetic technologists to detect any subpopulation of
amplified cells. Thirty representative nuclei from the inv-
asive tumor were scored by each technologist (60 nuclei
total), with an overall evaluation performed by a board-
certified pathologist (R.P.K., R.B.J.). When the red HER2
signals were clearly amplified (large clouds of amplifica-
tion), we assigned ≥20 red signals and counted the green
(CEP17) signals. For such cases, a number needs to be de-
fined for the numerator and thus the ratio was defined as
20/average number of green signals per cell. As polysomy
17 (p17) increases, the ratio decreases. Scoring ranges
were based on those determined for the US Food and
Drug Administration-approved test for HER2 gene al-
terations in breast cancer (BC). A specimen with an
HER2/CEP17 ratio ≥2.0 in invasive cells was classified
as HER2 amplified and considered HER2 positive ac-
cording to pre-ASCO/CAP 2007 guidelines [29].
Because many different HER2 and chromosome 17 alter-
ations have been observed in BC, we independently catego-
rized the HER2 FISH results on the basis of HER2 and
CEP17 signal patterns [33–37]. For HER2-amplified tumors
(HER2/CEP17 ratio ≥2), three ranges of CEP17 signals were
observed: p17, ≥3 CEP17 signals in more than 30 % of nu-
clei; monosomy 17 (m17), 0 to 1 CEP17 signals in more
than 60 % of nuclei; and normal (n17) all other cases. We
carefully validated these polysomy and monosomy cutoffs
by extensively analyzing our N9831 data and a large set
(>10,000 cases) of clinical HER2 FISH assays concurrently
performed by the central testing laboratory. Both cutoffs
clearly distinguish chromosome 17 polysomic and mono-
somic cases from those cases without chromosome 17
centromere anomalies. All categorization thresholds were
selected to reduce the rate of false-positive findings for
gene amplification, gene deletion, and chromosome loss
or gain. In our experience, these criteria have worked well
to correct for truncation and nuclear overlap and the in-
crease in four CEP17 signals due to G2M for nearly all
solid tumors.
Quality control of the HER2 FISH test is assessed rou-
tinely according to standard College of American Pathol-
ogists and the American College of Medical Genetics
guidelines. The performance of the assay as assessed on
a monthly basis has been stable according to Westgard
rules [38].
Eligibility criteria for N9831 trial enrollment were ini-
tially based on local laboratory HER2 test results (IHC
score of 3+ or HER2/control probe ratio ≥2.0 or five or
more gene copies of HER2) [12, 32]. After analysis of the
first 119 specimens showed poor concordance between
HER2 results from local and central (Mayo Clinic) labora-
tories, the protocol was amended (amendment 7), to re-
quire validation of HER2 positivity by the central laboratory
for eligibility and study participation [32]. When the central
laboratory’s IHC and FISH test results were both negative,
the local site was contacted and another set of slides was
submitted to a reference laboratory (Laboratory Cor-
poration of America, Research Triangle Park, NC, USA).
Enrollment into N9831 was then allowed only if HER2
positivity could be confirmed by IHC or FISH performed
in the central or reference laboratories [12]. One hundred
three patients with HER2-normal tumors (as shown by
central laboratory IHC and FISH test results) continued in
the trial because of local laboratory positivity (90 patients
enrolled before amendment 7 was established) or because
of reference laboratory positivity (13 patients enrolled after
amendment 7). In the present analyses, HER2 status by
IHC and FISH are based on the central laboratory tests
originally done at Mayo Clinic after local laboratory test-
ing being positive for HER2.
HER2 mRNA testing methods
The Oncotype DX breast cancer assay was performed as
previously described for all available specimens with in-
vasive carcinoma tissue (tumors were microdissected if
there were less than 50 % carcinoma or if any contami-
nants were present, e.g., biopsy cavity elements or skin)
[39]. All pathology was conducted blinded to clinical out-
come. Microscopic tumor size was from pathology reports.
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Tumors were graded using the Nottingham system
[40–42]. Tumors with less than 2.0 mm of invasive
carcinoma were excluded. FPE tumor tissue was depar-
affinized using Shandon xylene substitute followed by
ethanol washes. RNA was extracted using Agencourt
FormaPure kit (Beckman Coulter, Beverly, MA, USA),
and treated with DNase I. All samples were confirmed
free of genomic DNA by a β-actin-specific TaqMan®
PCR assay. Total purified RNA content was quantified
by Ribogreen® (Life Technologies, Carlsbad, CA, USA).
Reverse transcription priming with random hexamers
and gene-specific sequences was conducted using Omnis-
cript RT kit (Qiagen, Valencia, CA, USA). TaqMan® PCR
reactions were conducted in 384-well microtiter plates on
ABI 7900HT (Applied Biosystems, Foster City, CA, USA)
instruments. Gene expression was quantified by cycle
threshold (CT) method, where expression was deter-
mined from the fractional number of cycles required to
achieve a defined expression threshold. Gene expression
was measured in triplicate, aggregated at the gene level,
and normalized to the aggregate of five reference genes
(ACTB, GAPDH, GUSB, RPLP0, and TFRC). Reference
normalized expression ranged from 2 to 15 units where a
1-unit step corresponded to an approximate 2-fold change
in RNA content. Prespecified analytical and quality
metrics were applied as part of the rigorous, federally
regulated Clinical Laboratory Improvement Amen-
dments (CLIA) process. HER2 mRNA expression, in-
corporated into the 21-gene panel of the Oncotype DX
assay, was quantified, reference normalized, and reported as
a single gene value. In accordance with CLIA requirements,
HER2 expression range was qualified on each ABI 7900HT
PCR unit using daily control standards corresponding to
low and high gene expression levels, and data were verified
prior to processing N9831 study samples. HER2 (ERBB2)
expression levels corresponding to HER2 negative, equivo-
cal, and HER2 positive were previously specified as <10.7,
10.7 to <11.5, ≥11.5, respectively. The cutoff for HER2 posi-
tivity by RT-PCR was initially identified in an exploratory
analysis of 62 cases with IHC results (17 of which also had
FISH results) [20]. This cutpoint was further examined in
four studies that compared HER2 by RT-PCR with HER2
by IHC involving 78 cases [43], 249 cases [44], 45 cases
[45], and 80 cases [46]. Based on these data, another cut-
point to establish an equivocal range was identified to align
with the 2007 ASCO/CAP guidelines for HER2 testing,
prespecified and validated in two subsequent positive clin-
ical validation studies [22, 23].
Study design and endpoints
The prespecified primary endpoint for the correlative
quantitative gene analysis reported herein was distant
recurrence-free interval (DRFI, i.e., time to distant recur-
rence), defined as the time (in years) from randomization
to distant recurrence. The time to event for patients who
died without distant recurrence was considered censored
at the time of death, and local/regional recurrences were
ignored. Disease-free survival (DFS) was a secondary end-
point, defined as the time from randomization to local,
regional or distant recurrence, contralateral breast cancer
including ductal carcinoma in situ, other second primary
cancers, or death from any cause. DFS was censored at
the last date that the patient was known to be to be DFS
event-free.
The patients in this study were from either Arms A or
C and had a successful Oncotype DX assay, including
both recurrence score (RS) and quantitative HER2 single
gene results. All patients had both central IHC and FISH
assessments as part of the parent N9831 study. Mayo
Clinic IRB was the ethical body that approved our study.
Statistical analysis
For the primary analysis, a multivariable Cox regression
model, adjusting for nodal status (0, 1–3, 4–9, and 10+
positive nodes) as a main effect, was used to estimate
the association between HER2 expression level and the
benefit of trastuzumab for distant recurrence, comp-
aring Arm C to Arm A. A natural cubic spline model
with 2 degrees of freedom was used to allow for a po-
tentially nonlinear association, and a likelihood ratio test
was used to test for the significance of the ability to pre-
dict trastuzumab benefit. Statistical power was prospect-
ively estimated at ≥90 % assuming there would be 88 and
47 evaluable patients with distant recurrences in Arms A
and C (there were 102 and 45), respectively.
Additional Cox models were used to estimate the asso-
ciation between HER2 status by RT-PCR, IHC or FISH
and the benefit of trastuzumab for distant recurrence.
Kaplan-Meier estimates were generated for the propor-
tion of patients free of distant recurrence as a function
of time, and comparisons between groups were done
using log-rank tests. Concordance of HER2 assessments
was assessed according to the 2013 ASCO/CAP guide-
lines for HER2 testing [47]. All hypothesis tests were con-
ducted at the 0.05 significance level, and two-sided p values
and two-sided confidence intervals are reported.
The Oncotype DX assay was performed by Genomic
Health, while blinded to the N9831 study data, and sta-
tistical analyses were conducted jointly by the Alliance
and Genomic Health, Inc. This study was approved by
the North American Breast Cancer Group (NABCG)
Correlative Sciences Committee. See the detailed statis-
tical methods for further information (Additional file 1).
Results
Of the 2289 patients registered to Arms A or C in the
parent N9831 trial, 1936 were clinically eligible, and 1032
formalin FPE tumors were processed by Genomic Health,
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Inc., of which 901 (87.3 %) had successful Oncotype DX
assay results and were included in this analysis (Fig. 1). Of
the 131 samples processed without successful assays, 55
(42.0 %) did not meet pathology criteria for the assay (in-
sufficient or no tumor tissue or not primary tumor), 72
(55.0 %) had insufficient RNA, and 4 (3.1 %) did not meet
RT-PCR quality metrics. Thus, 475 patients from Arm A
and 426 from Arm C were analyzed for this study.
Patient characteristics
Patient and tumor characteristics for the 901 patients
included in this study are summarized in Table 1. The
distributions of patient and tumor characteristics were
compared between patients included in this study and
the 1029 patients who were clinically eligible but not in-
cluded in this study. There were no statistically significant
differences, except for tumor size where, not unexpectedly,
there was a slight shift toward larger tumor sizes among
the patients included in this study relative to those not in-
cluded (p = 0.03, Table 1). One hundred forty-seven distant
recurrence events were observed during a median follow-
up of 7.4 years.
Assessments of HER2 by IHC, FISH and RT-PCR
The pairwise concordance between HER2 mRNA expres-
sion level by RT-PCR, protein assessment by IHC, and
gene copy number assessment by FISH, was assessed ac-
cording to updated 2013 ASCO/CAP guidelines, in which
equivocal assessments are classified with HER2-negative
cases (Table 2). Among patients who were HER2 positive
by local assessment and, after the early protocol amen-
dment, by either central or reference assessment, overall
concordance was high among the pairs of HER2 measures:
87.6 % between central IHC and RT-PCR, 84.4 % between
central FISH and RT-PCR, and 85.8 % between central
IHC and central FISH. The positive concordances of RT-
PCR and central IHC (83.8 %) and of RT-PCR and central
FISH (87.8 %) were comparable to that of central IHC and
central FISH (88.9 %). The negative concordance of RT-
PCR and central IHC (86.6 %) was similar to that of RT-
PCR and central FISH (89.8 %), and greater than that of
central IHC and central FISH (58.0 %). Among the 51 pa-
tients who were centrally negative by both IHC and FISH,
46 were 3+ by local IHC with no FISH result, and the
remaining 5 were FISH-positive with no IHC result (ratios
of 2.00, 2.15 and 2.20, with two missing ratio information).
Concordance of HER2 status by RT-PCR and FISH, strati-
fied by estrogen receptor (ER) status by IHC, showed a
higher positive concordance in IHC ER-negative versus
IHC ER-positive cases (88.5 % versus 78.6 %) (Additional
file 2).
The association between the continuous HER2 mRNA
expression by RT-PCR (log2 expression level) versus
central HER2 by IHC is discernible (Spearman rank
correlation = 0.54, 95 % CI 0.49–0.58), although there
are broad ranges in HER2 expression level by RT-PCR
within each IHC category (Fig. 2).
The association between continuous HER2 by RT-
PCR and continuous central FISH ratio is depicted in
Fig. 3. The Spearman rank correlation is 0.49 (95 % CI
Fig. 1 CONSORT diagram. *Reasons for clinical ineligibility: failed central and reference laboratory review for HER2 positivity (193), patient cancelled (22),
patient lost to follow-up (96), and other reasons for clinical ineligibility (42), where the numbers are combined for Arms A and C. Note that Arm A includes
148 otherwise eligible patients who were enrolled during the Arm C closure
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0.44–0.54), similar to that between RT-PCR and cen-
tral IHC.
Among the 882 patients with central IHC, FISH and RT-
PCR assessments, all of whom were locally HER2 positive
by IHC or FISH, 62 (7.0 %) cases were negative by both
RT-PCR and central FISH, 25 of whom were also negative
by central IHC.
Prediction of trastuzumab benefit by assessment of HER2
In the primary analysis, continuous HER2 mRNA expre-
ssion level by RT-PCR was not significantly associated with
the magnitude of benefit from the addition of trastuzumab
to adjuvant chemotherapy (nonlinear p = 0.057, Fig. 4).
Hence, in this study of patients with locally HER2-positive
tumors by IHC or FISH, and confirmed centrally in
94 % of patients, the hypothesis of increasing trastuzumab
benefit with increasing HER2 mRNA expression was not
supported.
To further explore this observation, Cox proportional
hazards models were used to estimate the treatment effect
of trastuzumab, adjusted for nodal status (0, 1–3, 4–9 and
10+ positive nodes), overall and in different patient sub-
sets. Hazard ratios for trastuzumab benefit are depicted in
a forest plot, along with associated 95 % confidence in-
tervals (Fig. 5). In all 901 patients, the addition of tras-
tuzumab halved the risk of distant recurrence (hazard
ratio = 0.50, p < 0.001). When stratified by HER2 status
by RT-PCR, the hazard ratios for trastuzumab treat-
ment were 0.31 (95 % CI 0.09–0.83) for HER2-negative,
0.44 (95 % CI 0.09–1.59) for HER2-equivocal, and 0.55
(95 % CI 0.37–0.81) for HER2-positive patients. There
was a statistically significant benefit of trastuzumab in
patients who were HER2 negative by RT-PCR, and in pa-
tients who were HER2 negative by central FISH. In the
IHC-negative patients, and in the 44 patients who had
negative central assessments of IHC, FISH and RT-PCR,
there were nonsignificant hazard ratios toward benefit
from trastuzumab. Of note, all of the 95 % confidence
intervals for the hazard ratio for trastuzumab benefit
overlapped with the overall hazard ratio of 0.50.
For secondary endpoint DFS, there also was no associ-
ation between trastuzumab benefit and continuous HER2
by RT-PCR (p = 0.21). In patients who were HER2 negative
by RT-PCR, the hazard ratio for trastuzumab treatment
was 0.55 (95 % CI 0.26–1.12, p = 0.11). The hazard ratios
for trastuzumab benefit were 0.81 (95 % CI 0.25–2.40) for
HER2-equivocal, and 0.67 (95 % CI 0.49–0.90) for HER2-
positive patients.
Exploratory analyses of HER2 expression, hormone
receptor status and prediction of trastuzumab benefit
Exploratory analyses were performed to evaluate the joint
distribution of ER expression and HER2 expression, assess
Table 1 Patient and tumor characteristics: comparison or
included versus not included clinically eligible patients
Characteristic Clinically eligible
and included
(n = 901)
Clinically eligible
but not included
(n = 1029)
p value*
Arm assignment
A 475 (53 %) 548 (53 %) 0.81
C 426 (47 %) 481 (47 %)
Age at randomization
(years)
18–39 150 (17 %) 162 (16 %) 0.94
40–49 299 (33 %) 352 (34 %)
50–59 292 (32 %) 344 (33 %)
≥60 160 (18 %) 171 (17 %)
Menopausal status
Premenopausal 480 (53 %) 551 (54 %) 0.90
Postmenopausal 421 (47 %) 478 (46 %)
Extent of surgery
Breast sparing 354 (39 %) 396 (38 %) 0.72
Mastectomy 547 (61 %) 633 (62 %)
Extent of nodal
examination
Axillary node
dissection
816 (91 %) 925 (90 %) 0.62
Sentinel biopsy 85 (9 %) 104 (10 %)
Histologically positive
nodes
0 125 (14 %) 132 (13 %) 0.82
1–3 424 (47 %) 497 (48 %)
4–9 233 (26 %) 262 (25 %)
≥10 119 (13 %) 138 (13 %)
Tumor size (cm)
≤2.0 340 (38 %) 429 (42 %) 0.03
2.1–4.9 481 (53 %) 532 (52 %)
≥5 80 (9 %) 68 (7 %)
Tumor grade
1 16 (2 %) 12 (1 %) 1.00
2 233 (26 %) 274 (27 %)
3 641 (71 %) 730 (71 %)
Unknown 11 (1 %) 13 (1 %)
Hormone receptor status
ER or PR positive 481 (53 %) 552 (54 %) 0.89
ER and PR negative 420 (47 %) 476 (46 %)
Unknown - 1 (<1 %)
ER estrogen receptor, PR progesterone receptor
*p value from chi-square test for nominal categories or Cochran-Mantel-Haenszel
test for ordered categories
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Table 2 Concordance of HER2 status by RT-PCR, IHC, and FISH
HER2 status by RT-PCR Concordancea Positive concordance and negative
concordanceNegative Equivocal Positive Total
n (%) n (%) n (%) n (%)
Central HER2 IHC 0 14 (1.6) 1 (0.1) 1 (0.1) 16 (1.8) 87.6 % Pos. concordance = 87.8 %
1+ 19 (2.1) 6 (0.7) 0 (0.0) 25 (2.8) Neg. concordance = 86.6 %
2+ 58 (6.5) 25 (2.8) 18 (2.0) 101 (11.2) (Ref = IHC)
3+ 39 (4.3) 53 (5.9) 664 (73.9) 756 (84.2)
Total 130 (14.5) 85 (9.5) 683 (76.1) 898
HER2 status by RT-PCR 84.4 % Pos. concordance = 83.8 %
Negative Equivocal Positive Total
n (%) n (%) n (%) n (%) Neg. concordance = 89.8 %
Central HER2 FISH ratio <2 62 (7.0) 17 (1.9) 9 (1.0) 88 (10.0) (Ref = FISH)
≥2 64 (7.2) 65 (7.4) 667 (75.5) 796 (90.0)
Total 126 (14.3) 82 (9.3) 676 (76.5) 884
Central HER2 FISH ratio 85.8 % Pos. concordance = 88.9 % (Ref = FISH)
<2 ≥2 Total
n (%) n (%) n (%)
Central HER2 IHC 0 14 (1.6) 2 (0.2) 16 (1.8)
1+ 14 (1.6) 10 (1.1) 24 (2.7) Neg. concordance = 58.0 % (Ref = FISH)
2+ 23 (2.6) 76 (8.6) 99 (11.2)
3+ 37 (4.2) 706 (80.0) 743 (84.2)
Total 88 (10.0) 794 (90.0) 882
Positive concordance = (number of results positive by both methods)/(number of results positive by reference method)
Negative concordance = (number of results negative by both methods)/(number of results negative by reference method)
HER2 human epidermal growth factor receptor 2, RT-PCR reverse transcriptase polymerase chain reaction, IHC immunohistochemistry, FISH fluorescence in situ
hybridization
aPer 2013 ASCO/CAP guidelines, equivocal values are classified as HER2 negative for purposes of calculating concordance. Hence, IHC = 0, 1+ and 2+ are classified
as HER2 negative and HER2 equivocal by RT-PCR is classified as HER2 negative
Fig. 2 Distribution of HER2 by RT-PCR according to central HER2 by IHC. HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry,
RT-PCR reverse transcriptase polymerase chain reaction
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the effect of trastuzumab treatment by hormone receptor
(HR) status, and the association between HER2 expression
and trastuzumab benefit by HR status. A scatterplot of ER
expression by RT-PCR versus HER2 expression by RT-
PCR, stratified by ER status by local IHC (Additional
file 3), indicates that these two measures are uncorre-
lated for tumors that are ER negative by IHC (Spearman
rank correlation = -0.01, 95 % CI -0.10 to 0.09), but among
tumors that were ER positive by local IHC, higher ER ex-
pression by RT-PCR was associated with lower HER2 ex-
pression by RT-PCR (Spearman correlation = -0.35, 95 %
CI -0.43 to -0.27). However, a wide distribution of ER ex-
pression was seen regardless of HER2 expression level.
HR status was not a significant prognostic factor for
DRFI in Cox models adjusted for nodal status, whether
assessed by local IHC (p = 0.15) or RT-PCR (p = 0.86).
Moreover, consistent with the N9831 parent trial results,
a statistically significant trastuzumab benefit for distant
recurrence was observed in both HR-positive and HR-
negative subsets of patients, whether measured by local
IHC or RT-PCR (Additional file 4), and no interaction
between treatment and HR status was observed in Cox
models adjusted for nodal status (p = 0.37 for HR status
by local IHC and p = 0.18 for HR status by RT-PCR).
However, different results were obtained for DFS. HR
status (positive versus negative) was a significant prog-
nostic factor for DFS in Cox models adjusted for nodal
status, whether assessed by local IHC (HR = 0.64, 95 %
CI 0.49–0.83, p <0.001) or by RT-PCR (HR = 0.77, 95 %
CI 0.59–0.997, p = 0.047). A statistically significant trastuzu-
mab benefit for DFS was observed in HR-positive patients
(p = 0.003 for local IHC and p <0.001 for RT-PCR) but not
in the HR-negative subgroup (p = 0.13 and p = 0.36, re-
spectively). There was no interaction between treatment
and HR status by local IHC in a Cox model adjusted for
nodal status (p = 0.24) but a similar model for HR status by
RT-PCR indicated an interaction that did not quite achieve
statistical significance (p = 0.051). Thus, HR status was nei-
ther prognostic nor predictive of trastuzumab benefit for
DRFI, but prognostic with some evidence of differential
trastuzumab benefit for DFS.
In addition, the association between HER2 expression
level by RT-PCR and trastuzumab benefit was evaluated
separately in the HR-positive and HR-negative patient
subsets, using the same Cox model as in the primary
analysis. In patients who were HR negative by local IHC,
HER2 by RT-PCR was not associated with the magni-
tude of trastuzumab benefit for distant recurrence (non-
linear p = 0.69, Additional file 5). However, there was a
significant association between HER2 by RT-PCR and
trastuzumab benefit for distant recurrence in patients who
were HR positive by local IHC (nonlinear p = 0.0015); the
relationship was nonmonotonic, with large benefit at
lower and higher expression levels, and no benefit for
Fig. 3 Distribution of HER2 by RT-PCR according to central FISH ratio. FISH fluorescence in situ hybridization, HER2 human epidermal growth factor
receptor 2, RT-PCR reverse transcriptase polymerase chain reaction
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Fig. 5 Trastuzumab benefit by HER2 status by RT-PCR, FISH and IHC. FISH fluorescence in situ hybridization, HER2 human epidermal growth factor
receptor 2, IHC immunohistochemistry, RT-PCR reverse transcriptase polymerase chain reaction
Fig. 4 Hazard ratio for trastuzumab benefit as a continuous function of HER2 expression by RT-PCR. Estimate and 95 % confidence limits obtained from
a Cox PH model for DRFI with a main effect for treatment arm (C versus A), a natural cubic spline for the main effect of HER2 by RT-PCR, a natural cubic
spline for the interaction of HER2 by RT-PCR with treatment arm, and three indicator variables to adjust for nodal status (0, 1–3, 4–9 and 10+ positive
nodes). Solid line = estimate of hazard ratio; dashed lines= lower and upper 95 % confidence limits. DRFI distant recurrence-free interval, HER2 human
epidermal growth factor receptor 2, RT-PCR reverse transcriptase polymerase chain reaction
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intermediate levels (Additional file 5). This pattern was ex-
plored further by examining Kaplan-Meier plots of time
to distant recurrence comparing the two treatment arms
by quartiles of HER2 expression by RT-PCR. In patients
who were HR positive by local IHC, the greatest benefit
from trastuzumab was observed in the lowest and highest
quartiles of HER2 expression, with smaller benefit in the
second and third quartiles (Additional file 6).
The same methods for the primary analysis were applied
to continuous expression for each of the other 15 cancer-
related genes in the Oncotype DX assay, as well as the
recurrence score, and none were statistically significant
predictors of trastuzumab benefit.
Discussion
The primary aim of this prospectively designed study was
to determine if quantitative levels of the ERBB2 gene ex-
pression level as assessed by messenger RNA coding for
the HER2 protein quantified by the 21-gene assay and re-
ported as the HER2 single gene score are predictive of the
magnitude of benefit from the addition of trastuzumab to
adjuvant chemotherapy in NCCTG (Alliance) N9831. In
this study of patients who were locally HER2 positive by
IHC or FISH, continuous HER2 mRNA expression level by
RT-PCR was not significantly associated with the magni-
tude of benefit from the addition of trastuzumab to adju-
vant chemotherapy. Similarly, no association was observed
for central IHC or central FISH ratio. Thus, the hypothesis
of increasing trastuzumab benefit with increasing HER2
mRNA expression is not supported.
In all patients, the addition of trastuzumab approximately
halved the risk of distant recurrence. This effect was noted
both within RT-PCR HER2-positive and -negative patients.
In particular, there was a statistically significant benefit of
trastuzumab in patients who were HER2 negative by RT-
PCR. Similarly, there was a statistically significant benefit of
trastuzumab in patients who were HER2 negative by
central FISH. Moreover, the 25 patients who had a local
HER2-positive result (IHC or FISH), but negative central
assessments of IHC, FISH and RT-PCR showed a smaller
but nonsignificant hazard ratio toward greater benefit from
trastuzumab. NSABP B-47 will determine whether the
addition of trastuzumab to chemotherapy improves out-
come in women with resected node-positive or high-risk
node-negative breast cancer which is reported as HER2-
low by all HER2 testing performed.
Statistically significant trastuzumab benefit was observed
in both the HR-positive and HR-negative subsets of pa-
tients, whether measured by local IHC or RT-PCR [major-
ity ER positive and/or progesterone receptor (PR) positive].
Among tumors that were ER positive by local IHC, higher
ER expression by RT-PCR was associated with lower HER2
expression by RT-PCR, a relationship that is consistent with
prior reports on protein expression, gene amplification
status and gene expression [19, 48, 49]. Our data sug-
gest a complex relationship between HER2 and ER as
determinants of clinical benefit from trastuzumab added
to adjuvant chemoendocrine therapy. There was a non-
monotonic association between HER2 mRNA and trastu-
zumab benefit in the HR-positive subgroup.
Surprisingly, the HER2 subgroup with the least clinical
benefit from adjuvant trastuzumab actually had intermedi-
ately overexpressed—not the lowest—levels of HER2
mRNA, although the confidence intervals do not exclude
a clinically important benefit of trastuzumab for these
intermediate expression levels. This finding of a nonmo-
notonic interaction between HER2 expression and tra-
stuzumab benefit in patients with the highest levels of
ESR1-associated genes has been previously reported [50].
We cannot exclude clinical treatment benefit for any level
of HER2 expression in this study. This finding is likely
multifactorial and potential reasons for it include: that pa-
tients with tumors that express higher ER may have
already derived maximum clinical benefit from antiestro-
gen therapy, that these tumors are biologically resistant to
trastuzumab, or there is a complex interaction between
hormone therapy, chemotherapy and trastuzumab benefit
and tumor biology. These findings have prompted fur-
ther studies using advanced molecular techniques to
determine if other genes or gene groups will be better
predictors of trastuzumab benefit [51].
The secondary aim of this study was to assess concord-
ance among the three central assays. Overall concordance,
assessed based on the current ASCO/CAP guidelines, was
high for RT-PCR versus IHC (87.6 %) and FISH (84.4 %)
and similar to the concordance observed between central
IHC and central FISH (85.8 %) [10]. The concordance was
higher and comparable to the previously reported concord-
ance studies when calculated using the 2007 ASCO/CAP
guidelines [22, 23, 29]. The positive concordances of RT-
PCR and central IHC and of RT-PCR and central FISH
were comparable to that of central IHC and central FISH,
whereas the negative concordance of RT-PCR and central
IHC was similar to that of RT-PCR and central FISH, but
greater than that of central IHC and central FISH. Al-
though all patients were locally HER2 positive by IHC
or FISH, the clinical significance of these HER2 con-
cordance results in this randomized clinical trial pop-
ulation, N9831, is that they are consistent with, and
therefore supportive of, the high degree of concordance
of HER2 assessment by RT-PCR with central IHC and
FISH assays from prior randomized clinical trial and
cohort populations that are more representative for
HER2 testing [22, 23]. Although the concordance was
high for classification into positive and negative cat-
egories, the associations between the quantitative HER2
mRNA expression by RT-PCR and semiquantitative
central IHC and FISH measures was modest and there
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were broad ranges in HER2 expression level by RT-
PCR within each IHC/FISH category. The causes of this
variability are likely multifactorial. True biologic differ-
ences between RNA levels and DNA gene amplification
offer one possibility [5]. Sources of analytic variability
are another: not all FISH assays are the same nor are
all RT-PCR assays [52]. With respect to RT-PCR tech-
nology, differences in RNA extraction methods, reverse
transcription, PCR protocols, instruments, primer/probe se-
lection and reagent manufacturing can contribute to signifi-
cant assay variation. The Oncotype DX assay uses controls,
calibrators, reference ranges (for quantitative single gene ER,
PR and HER2 results) and utilizes normalization to address
differences in RNA quality [20, 53–55]. The variability (SD)
contributed by instruments, operators, reagents and day-to-
day variation for RT-PCR using Oncotype DX is less than
0.5 expression units [20, 21]. Sources of preanalytic variab-
ility (e.g., delay to fixation, choice of fixative or duration of
fixation) may also play a role and their impact in HER2 as-
sessment by FISH is well described [56, 57].
Our HER2 concordance results are not consistent with
those of Dabbs et al. [58]. Three institutions reported on
a predominantly ER-positive HER2-negative convenience
sample of 843 total cases: 36 (4 %) HER2 positive, 23
(3 %) equivocal and 784 (93 %) centrally HER2 negative
[58, 59]. Of the 784 HER2-negative patient cases, 779
(99 %) were classified as negative by RT-PCR while of
the 36 IHC/FISH-positive cases, by RT-PCR only 10
(28 %) were reported as positive, 12 (33 %) as equivocal,
and 14 (39 %) as negative. In only one of the three par-
ticipating institutions from that study, did the investiga-
tors retest the discordant cases, e.g., those cases that had
been IHC/FISH positive but RT-PCR negative (N = 9), in
which the repeat test used the same FPE block for all as-
says, IHC/FISH and RT-PCR. When the same block sent
for RT-PCR testing was retested using FISH, 44 % (4/9)
were converted from positive to equivocal. It is not clear
if these analyses were done in a blinded manner, whether
limited foci of amplification were used to call positivity,
or if these differences are due to heterogeneity. Tumor
cell dilution has also been suggested as a source of dis-
cordance; however, we assessed the percentage of tumor
cells and the tumor area and, consistent with the obser-
vation of Christgen et al., there were no significant dif-
ferences between concordant and discordant cases [25].
The discordances between FISH and IHC, and RT-PCR
and IHC and FISH again highlight that there are differ-
ences between HER2 assays and their targets. These dif-
ferences, and other factors including differences in
HER2 concordance as a function of ER status, further
demonstrate why definitive studies need to ideally be
done in large randomized trial populations with appro-
priate HER2 distributions and clinical outcomes in order
to minimize sources of potential bias [10, 25, 60, 61].
The strengths of this study include the large landmark
N9831 randomized trial population of patients with HER2-
positive breast cancer, randomized to chemotherapy ±
trastuzumab treatment, using high-quality central and ref-
erence laboratories with standardized methods for FISH
and RT-PCR assays [20, 21, 52, 62]. There are also some
limitations to consider when interpreting these study re-
sults. All patients had tumors that were deemed to be
HER2 positive using protein or gene analysis by local la-
boratories, and our findings may not be generalizable to the
broader patient population. Also, our study included only
47 % of the clinically eligible patients from the parent study,
although patient characteristics (except for tumor size)
were similar between patients included and not included.
Conclusions
In summary, our data do not show that trastuzumab bene-
fit increases with increasing HER2 mRNA expression. They
do support the high concordance with central IHC and
FISH assays as previously reported. We do not recom-
mend HER2 testing by RT-PCR replacing IHC or FISH
assays in standard practice.
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